AICT-AsiaPCR is one of the world’s leading conferences in interventional cardiovascular medicine that focuses on training and education. Nipro’s vascular team from Japan, South East Asia, and India landed in Singapore for AsiaPCR 2023 – one of the biggest stages for the vascular sector.

Key facts and figures

  • 700+ participants
  • 5 session rooms covering all the hot topics
  • Sponsored Programme
  • 330+ Faculty & Presenters
  • 6 LIVE Cases sessions
  • 396 submissions received
  • 18 topics
  • 13 supporting Industry Partners
  • Up to 11 CME credits

The unique event held in Singapore provided an ideal setting for us to meet with distributors, prospective clients, and potential partners. This setting facilitated conversations about the most recent advancements in intracoronary imaging, particular makoto intravascular imaging system and what lies ahead in the coming year.

Date: 21 – 22 September 2023

Venue: SUNTEC Convention and Exhibition Center. 1 Raffles Boulevard Singapore 039593

Come visit Nipro’s booth A09 at AICT-AsiaPCR 2023 in Singapore.

Congress information:

17th September is also known as “World Patient Safety Day”

World Patient Safety Day 2023 is dedicated to the theme “Engaging patients for patient safety” and the slogan “Elevate the voice of patients!” Nipro wishes to initiate this discussion, shedding light on the protection of both patients and healthcare professionals (HCPs).


Patient safety is essential for providing high-quality healthcare services, but it is a skill that needs honing. As healthcare facilities have become more complex, patient safety has evolved as a discipline. The rise in accidental harm to patients and HCPs, often due to errors, has prompted efforts to protect and reduce the risks and errors within healthcare settings.

Central to patient safety is PREVENTION:

  • Awareness: Includes risk assessment, continuous training and evaluations, and hands-on clinical education.
  • Systems: Encompasses policies, procedures, audits, and leadership support.
  • Products: Involves aseptic kits, safety devices, and built-in safety mechanisms.

Nipro specifically wants to address the importance of the last point.


Needlestick injuries (NSIs), where individuals are inadvertently pierced by needles or other sharp objects, can lead to exposure to blood or other bodily fluids. This is a grave matter, as unsafe injection practices and accidental punctures can transmit infections such as HIV, Hepatitis B or C, posing a direct threat to patients, HCPs, and waste management professionals, among others. In essence, anyone exposed to the needle is at risk, from its administration to its disposal.

Each year, patients and HCPs suffer from needlestick and sharps injuries, with predictions that 1 in 10 healthcare professionals will be exposed to bloodborne pathogens in the coming year. The World Health Organization estimates that 3 out of 35 million HCPs worldwide face exposure to bloodborne pathogens each year due to these needlestick injuries.

In fact, NSIs are responsible for a significant burden of harm, estimated at 9.2 million years of life lost to disability and death worldwide, referred to as Disability Adjusted Life Years (DALYs).

Furthermore, the CDC estimates that 5.6 million workers in the healthcare industry and related fields are at risk of occupational exposure to bloodborne pathogens. Needlestick injuries during routine occupational duties in 2010 accounted for roughly 40% of hepatitis B and hepatitis C infections, as well as 4.4% of HIV infections in healthcare workers.

The repercussions of an NSI are far-reaching:

  • Biological consequences
  • Psychological impact
  • Documentation and potential investigations
  • Follow-up medical examinations
  • Time expended
  • Additional costs

All of these ultimately place added pressure and stress on healthcare professionals and facilities.


While Nipro maintains an ongoing commitment to enhancing patient care year-round, this serves as an ideal opportunity to emphasize the importance of ensuring treatment safety and effectiveness for everyone, every day.

To ensure optimal treatment and instill confidence in end-users as HCPs care for patients daily, Nipro’s SafeTouch® line, featuring an irreversible safety mechanism, are designed to offer three critical benefits:

  • Maximizing user safety
  • Minimizing patient discomfort
  • Enhancing ease of use


Whether you’re a dialysis nurse, waste management professional, hospital administrator, or procurement manager, rest assured that Nipro can provide you with the tools to reduce risks and prioritize safety for everyone involved.

Today marked a historic moment as the first Makoto IVUS+NIRS sets sail from the Infraredx, a Nipro company – from the loading dock, en route to Australia.

We are thrilled to welcome back NIRS and Extended Bandwidth IVUS to the continent that witnessed their groundbreaking beginnings. In 2014, Adelaide saw the first evaluation of the world’s 2nd-to-market High Definition IVUS in patients.

Notably, this was where the very first NIRS corelab for data analysis was established, thanks to the pioneering efforts of Steve Nicholls at SAHMRI.

Fast forward to today, and the enthusiasm for these techniques has ignited strong interest in Japan, with some of the highest volume users and programs embracing this technology.

The future looks bright as we embark on this new chapter of medical advancement in Australia. Stay tuned for updates on this exciting journey!

We are pleased to announce an auspicious occasion as Nipro Sales Thailand proudly unveils its new Khon Kaen office. This momentous event marks a significant milestone for the company, representing our commitment to expansion and growth in the region.

Nipro, a global leader in healthcare solutions, has been at the forefront of innovation and catering to diverse medical needs for healthcare professionals and patients. With an unwavering dedication to improving the lives of patients worldwide, our organization has consistently pursued excellence in research, development, and manufacturing.

Against this backdrop, the establishment of the Nipro Sales Thailand’s Khon Kaen office opens up new horizons for our operations, further cementing our presence in Southeast Asia. This strategic move not only strengthens our ability to serve the local market but also reinforces our position as a trusted partner in the global healthcare community.

Khon Kaen, a vibrant city known for its rich cultural heritage and thriving economy, was carefully chosen as the site for our expansion. The city’s dynamic environment and growing medical landscape provide an ideal backdrop for Nipro’s continued growth. By establishing a local presence, we aim to foster closer collaboration with healthcare professionals, researchers, and industry partners in Khon Kaen and the surrounding areas.

The opening ceremony of the Nipro Sales Thailand Khon Kaen office promises to be a moment of celebration, bringing together distinguished guests, esteemed colleagues, and influential figures from the medical community. The event will showcase our state-of-the-art facilities, which have been designed to foster innovation and collaboration, driving us towards even greater advancements in healthcare technology.

Furthermore, the inauguration will provide an opportunity to highlight our commitment to corporate social responsibility. As a responsible corporate citizen, Nipro is dedicated to contributing to the well-being of the communities in which we operate. Through various initiatives and partnerships, we aim to make a positive impact on the lives of individuals in Khon Kaen and beyond.

We invite you to join us on this remarkable journey as we celebrate the opening of the Nipro Sales Thailand Khon Kaen office. Stay tuned for further updates as we embark on a new chapter of growth, innovation, and collaboration in healthcare.


On 24th March 2023, An Giang Central General Hospital held an inauguration ceremony of RO water system – Phoenix one DS + and the Workshop titled, “Cardiovascular: Renal – metabolic syndrome”.

This is one of the largest RO water system used in artificial kidney dialysis in South East Asia. Water is an indispensable part of dialysis – but in order to avoid complications, it should be of an ultra-pure quality.

The renowned An Giang Hospital in Vietnam, providing dialysis to about 350 patients regularly, understands this and recently installed Nipro’s Phoenix One DS – a single-stage reverse osmosis (RO) system – to provide better treatment to its patients. The Phoenix One DS is the first high-end product for this market and will provide quality treatment to patients.

On the day of the inauguration, there was also a renal seminar that attracted over 230 doctors. On this historic occasion, Nipro Vietnam was present in great numbers. Joining in attendance from Nipro’s regional team were Mahendra Gunatilleke, Rüdiger Tille and Jesus Garcia Martin.

Here’s the news report of the grand inauguration that was aired on a local television channel in Vietnam: you can choose to view it with subtitles (CC) or preferred auto-translation.

Inauguration ceremony of RO water system – Phoenix one DS + at An Giang Central General Hospital

Workshop titled, “Cardiovascular: Renal – metabolic syndrome”.

Date: 15 – 16 April 2023

Venue: Novotel Singapore on Stevens, Polaris Ballroom, Level 1
28 Stevens Rd, Singapore 257878

Congress & Exhibition Hours:
Saturday, 15 April 2023, 0830 – 1730 hrs
Sunday, 16 April 2023, 0830 – 1215 hrs

Come visit Nipro’s booth this weekend at APAC 2023 in Singapore.

The Asia Primary Angioplasty Congress (APAC) is a dedicated primary angioplasty meeting in the region. Don’t miss out.

Congress information:


Nipro will be participating in the World Congress of Nephrology (WCN), which is an annual scientific, educational, and networking meeting of the International Society of Nephrology (ISN). Come check us out at our booth as there will be many activities awaiting for you. Mark you calendar and we hope to see you there soon!

Date: 30th March – 2nd April 2023
Time: 08:00AM-08:00PM in Bangkok, Thailand Time (GMT+7)
Venue: Queen Sirikit National Convention Center, Bangkok, Thailand
Booth: Ballroom, Plenary Hall , Level 1, Booth #14
Activities: Vascular workshop, iMEP Thailand training courses & Renal care portfolio

Register your interest

Fill in this form if you’d like us to follow up with you after event:

    Select Product of Interest (required) *
    Would you like to hear more from your local representative? (required) *

    ISN WCN 2023 website:

    Nipro Asia participated in the 32nd Singapore Live – Asia’s pre-eminent annual live course in cardiac interventions that was held at the Raffles City Convention Centre in Singapore from the from the 12th – 14th of January. 900 local and regional delegates from over 34 countries participated this year.

    This marks the first time that Nipro has participated in a SingLIVE event with an expanding vascular intervention portfolio that was featured during a live case, an event booth, and a symposium. On the first day of the event at 10:15a.m., alive case using the Makoto Intravascular Imaging System and Aperta NSE was live streamed by the NHCS.

    The live case was performed by Clinical Associate Prof. Jack Tan and his team from the National Heart Centre. The NHCS operation team showcased the Near Infrared Spectroscopy (NIRS)-guided Percutaneous Coronary Intervention (PCI), its application as a coronary imaging tool as well as tips and tricks on its utilization. Makoto utilizes NIRS in combination with intravascular ultrasound (IVUS) is a state-of-the-art technology developed for coronary lipid-plaque characterization.

    Recent studies have evaluated its clinical utility as well as how to integrate its use into clinical practice. The information for the prediction of the major adverse cardiac event (MACE) was something new and more than 100 audience members gathered to see the live case, which brought the discussion among the panelists on how the information provided by Makoto could change the treatment plan.

    The day followed with Nipro’s symposium titled “Seeing is believing: Lesion preparation and Lipid core detection”. The in-depth presentation was made by A. Prof. Kosuke Koyama who talked about clinical studies of IVUS-NIRS technology, and Dr. Satoru Tohara who presented findings about Aperta NSE as a preferred scoring balloon.


    Lesion Preparation and Lipid Core Detection in Daily Practice

    Date: 12th January 2023
    Time: 14:00-15:00 in Singapore Standard Time (GMT+8)
    Venue: Sophia Ballroom, Raffles City Convention Centre, Singapore

    Understand the utility of a scoring balloon in clinical practice.
    – Learn the utility of IVUS-NIRS (Near Infrared Spectroscopy) in daily practice.

    Chairperson: LIM Soo Teik
    Panelists:  AL FAZIR Omar, Kohei KOYAMA, Jack TAN, Satoru TOHARA

    • Opening by LIM Soo Teik
    • Clinical advantage of NIRS-IVUS guided PCI by Kohei KOYAMA
    • Panel discussion
    • Clinical utility of Aperta NSE – my preferred choice of  scoring balloon by Satoru TOHARA
    • Panel discussion
    • Closing by LIM Soo Teik

    LIVE CASE of IVUS + NIRS Imaging with makoto

    The latest technologies provided by NIPRO will be live-streamed
    by the National Heart Centre, Singapore.

    • Live case from National Heart Centre Singapore Operator: Jack TAN, KEH Yann Shan
    • Panel discussions

    Time: 10:15-11:10 in Singapore Standard Time (GMT+8)
    Venue: Stamford Ballroom, Raffles City Convention Centre, Singapore

    Invitation PDF:

    Singapore Live 2023 Programme:

    Notice of Establishment of Medical Device Sales Subsidiary in the Philippines

    We are pleased to announce that one of its consolidated subsidiaries, Nipro Asia Pte. Ltd. (Head office: Singapore, President: Seigo Tsuchiya), has established a medical device sales subsidiary—Nipro Medical Philippines Corp.—in the Republic of the Philippines.

    Sales are scheduled to begin at this new subsidiary in January 2023. Nipro Asia has been actively selling medical devices in the Philippines, an ASEAN member with a rapidly growing economy, mainly through local distributors. However, in December 2021, Nipro Asia established a sales subsidiary in Manila, the largest city in the Philippines, in anticipation of further market expansion.

    Nipro Asia intends to further enhance the presence of the NIPRO brand by establishing a direct sales system for the company’s dialysis products, by strengthening the promotion of the sale of hospital products, vascular products, and infection control products, and by providing attentive services with deep community ties.

    Overview of New Subsidiary

    (1)Name: Nipro Medical Philippines Corp.
    (2) Representative: Takato Senoo (President)
    (3) Location: Taguig City, Manila, Republic of the Philippines
    (4) Establishment date: December 1, 2021
    (5) Business start date: January 1, 2023 (Scheduled)
    (6) Capital: 75,000,000 PHP
    (7) Business outline: Sales of medical devices, and establishment/operation
    management of a NIPRO dialysis center